Real-world EHR data suggest ACE inhibitor use is independently associated with lower all-cause mortality in idiopathic pulmonary fibrosis, while no similar survival association was observed in COPD.

Among patients with idiopathic pulmonary fibrosis, the risk for all-cause mortality was significantly lower with vs. without angiotensin-converting enzyme inhibitor use started within 5 years before ...